Interson receives FDA clearance for ultrasound probes

AuntMinnie.com staff writers
Jun 14, 2017

Ultrasound probe manufacturer Interson has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the use of its Simpli series of linear and convex array ultrasound probes in human applications.

The lightweight probes, which can be connected to Windows OS tablets, laptops, and desktops with the USB probe cable, are suitable for point-of-care applications such as primary care, long-term care, rehabilitation, telemedicine, and women's health, according to the company. The Simpli series has been available for veterinary applications since January.

Latest in Ultrasound
Ultrasound Diagnostic Control Panel 400
Ultrasound falls short for detecting endometrial cancer in Black women
February 21, 2025
1Each lung has been split into three parts. Each area has been given a score between 0 and 3. Score values are shown in Ultrasonograms to match 4 different patterns. During a longitudinal scan with a high-resolution linear probe, pictures of patterns were taken. The scores are as follows: 0 means A pattern, 1 means B pattern, 2 means severe B pattern, and 3 means extended consolidation. Images available for publishing under a creative commons license, CC BY-NC-ND 4.0.
LUS reliable for care strategies in infants with RDS
February 20, 2025
2025 02 19 Ajr Lung Images Thumbnail
Lung biomarkers inform patient selection for EBUS-TBNA
February 19, 2025
Lung Cancer
Ultrasound rules out N2 disease in PET-negative lung cancer patients
February 12, 2025
        An unexpected error occurred: Network error: Response not successful: Received status code 500
      
            [
  {
    "message": "Cannot execute GraphQL operations after the server has stopped.",
    "extensions": {
      "code": "INTERNAL_SERVER_ERROR"
    }
  }
]
More in Ultrasound
Ultrasound falls short for detecting endometrial cancer in Black women
By Amerigo Allegretto
Ultrasound-based strategies fall short of biopsy for detecting endometrial cancer in non-Hispanic Black women.
February 21, 2025
Ultrasound Diagnostic Control Panel 400
LUS reliable for care strategies in infants with RDS
By Amerigo Allegretto
Lung ultrasound (LUS) scoring is reliable for determining whether preterm newborns need surfactant for suspected respiratory distress syndrome (RDS).
February 20, 2025
1Each lung has been split into three parts. Each area has been given a score between 0 and 3. Score values are shown in Ultrasonograms to match 4 different patterns. During a longitudinal scan with a high-resolution linear probe, pictures of patterns were taken. The scores are as follows: 0 means A pattern, 1 means B pattern, 2 means severe B pattern, and 3 means extended consolidation. Images available for publishing under a creative commons license, CC BY-NC-ND 4.0.
Lung biomarkers inform patient selection for EBUS-TBNA
By Amerigo Allegretto
Lung imaging biomarkers can inform patient selection for endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA).
February 19, 2025
2025 02 19 Ajr Lung Images Thumbnail
Ultrasound rules out N2 disease in PET-negative lung cancer patients
By Amerigo Allegretto
Combined endobronchial ultrasound and endoscopic ultrasound is a reliable tool for ruling out N2 disease in PET-negative lung cancer patients.
February 12, 2025
Lung Cancer
Cryoablation leads to low breast cancer recurrence rates
By Amerigo Allegretto
Ultrasound-guided cryoablation can be considered for breast cancer patients who are poor surgical candidates or who refuse surgery.
February 7, 2025
Breast Cancer
Ultrasound, histopathological diagnoses assess benign breast lesions
By Amerigo Allegretto
Sonographic imaging descriptors and histopathological diagnoses are needed for more accurate assessment of benign breast lesions.
February 3, 2025
Ultrasound Breast 400
AI assistance improves CHD detection on prenatal ultrasound
By Amerigo Allegretto
AI boosts detection of major congenital heart defects (CHDs) on prenatal ultrasound, suggest findings presented at the Annual Pregnancy Meeting of the SMFM.
January 31, 2025
Smfm Ultrasound Ai Fetal Thumbnail
LI-RADS ultrasound surveillance version 2024 improves HCC detection
By Amerigo Allegretto
The 2024 version of the LI-RADS Ultrasound Surveillance system improves detection of hepatocellular carcinoma (HCC) over earlier iterations.
January 22, 2025
(A,B) Images from an initial ultrasound examination showed no identifiable lesions and received a consensus ultrasound category of US-1. Nearly the entire liver is visualized, with minimal shadowing (“s”, A and B), and the examination received consensus result of VIS-A. The AFP level was 7.1 ng/mL on assessment six months before the ultrasound, 9.1 ng/mL on assessment three months before examination, and 14.2 ng/mL on assessment on exam day. The AFP result was thus assessed as positive based on a progressive increase on two consecutive tests. The atient was considered to have negative surveillance result according to LI-RADS Ultrasound Surveillance v2017, but positive surveillance result according to LI-RADS Ultrasound Surveillance v2024. (C-D) Axial arterial-phase (C) and portal-venous phase (D) T1-weighted images from subsequent gadoxetic acid-enhanced MRI show a 2-cm arterial-phase hyperenhancing observation (arrow, C) with portal-venous washout (arrow, D) in segment 7. This observation was classified on MRI as LR-5, thus meeting the present study’s reference standard for diagnosis of HCC. The mass is located in the periphery of the liver, an anatomic area where ultrasound visualization can be challenging due to shadowing.
CEUS resolves indeterminate CT, MRI liver observations
By Amerigo Allegretto
Contrast-enhanced ultrasound (CEUS) can resolve some high-risk indeterminate liver observations initially seen on CT or MRI.
January 21, 2025
Images depict a 49-year-old female participant with cryptogenic cirrhosis who presented with a 3.2-cm liver lesion. This biopsy-confirmed hepatocellular carcinoma (HCC) with an initial categorization of Liver Imaging Reporting and Data System (LI-RADS) category LR-4 (probably HCC) at CT was upgraded to LR-5 (definitely HCC) at contrast-enhanced ultrasound (CEUS). (A) Precontrast CT images in the liver show vague hypoattenuation in the medial left hepatic lobe (arrows). (B) Arterial phase images demonstrate no definite arterial phase hyperenhancement (arrows). (C) Washout and an enhancing capsule (arrows) on a late-phase image resulted in an LR-4 categorization. (D) B-mode ultrasound shows a round hypoechoic nodule (arrows). (E) An early-phase CEUS image shows clear arterial-phase hyperenhancement (arrows); (F) No washout at one minute (arrows), and (G) late, mild washout at four minutes (arrows) resulted in a CEUS LR-5 categorization.
POCUS useful for diagnosis of retained conception tissue
By Amerigo Allegretto
Point-of-care ultrasound (POCUS) can be a useful tool for diagnosing the presence of retained conception tissue.
January 15, 2025
Ultrasound Portable
AI guidance leads to better LUS image acquisition by novice users
By Amerigo Allegretto
Healthcare professionals who are not sonography experts can successfully acquire lung ultrasound (LUS) images with AI assistance.
January 15, 2025
Ultrasound Probe2 Social
Ultrasound ablation is effective for treating hyperparathyroidism
By Amerigo Allegretto
Ultrasound-guided thermal ablation techniques are safe and effective in treating patients with secondary hyperparathyroidism.
January 7, 2025
Ultrasound images depict a 63-year-old man who underwent radiofrequency ablation (RFA) for the treatment of secondary hyperparathyroidism. (A–D) 2D images show four hyperplastic parathyroid glands on the right and left sides (marked with crosshairs). The numbers near the crosshairs represent the number of measured trails. (E) Ultrasound-guided infusion of isolation fluid (arrowheads) around the hyperplastic parathyroid gland to protect vital organs such as the trachea (Tr), carotid arteries (CA), and recurrent laryngeal nerve pathway area (arrow). F) Ultrasound-guided RFA of the hyperplastic parathyroid gland. (G) Immediate postoperative contrast-enhanced ultrasound shows no contrast enhancement in the ablation area. The ablation procedures for the other three parathyroid glands were the same as those described above. Image courtesy of the RSNA,
Page 1 of 513
Next Page